Biology students using 3D technology in the classroom

To view our videos, you need to enable JavaScript. Learn how. install Adobe Flash 9 or above. Install now. Then come back here and refresh the page.

The shades are on during this biology class at Broadalbin-Perth High School. The reason...3D technology.

Biology teach Brian Henry said, "It's been nothing short of spectacular in regards to teaching certain elements of biology and allowing students to view it in a completely different world."

Students viewed three dimensional models and instructional videos featuring, for example, the pumping of a human heart or photosynthesis.

Henry said, "The images pop out at them. They can almost reach out and touch them, and they are completely engaged from the minute they put their glasses on to the time the bell rings, and from an education standpoint you can't ask for anything more than that."

And that seems to be the case here. Upon first look, it's obviously different than a traditional learning tool we all know - the textbook.

Student Cody Husek said, "Being handed a diagram on a piece of paper and you're expected to look at it hard and look at the ventricles, I think it's a lot easier to get something out of it when you can see it on three dimension with something like this."

Henry said, "When you throw a 3D projection out there and the animations come to life, all of a sudden those kids that weren't engaged at one point are the first ones raising their hands, what's this all about, can we do this, etc."

Along with the visuals, this program also speaks for itself.

Each unit is on "loan" for participating schools across the state , and then they are returned to the district's regional information center. For a school to own one, they run about $16,000 each. But as advanced as this is, it's also the world we live in.

View original post here:
Biology students using 3D technology in the classroom

Nobel Laureate Explores Proteins, Surgery

Nobel Laureate in Chemistry Roger Tsien discussed current research on fluorescent proteins, or proteins that emit bright colors when exposed to ultraviolet blue light, and their uses in surgery at Emory on Thursday.

The Department of Biochemistry held the lecture, titled Breeding and Building molecules to Spy on Cells and Disease Processes, at the Woodruff Health Sciences building as part of the Department of Biochemistrys annual Donald B. McCormick Lecture. The annual lecture honors McCormick, who served as the chair of the department from 1979 to 1994 and is currently professor emeritus at Emorys School of Medicine.

McCormick is recognized for his many achievements including the publication of more than 500 papers, leading expertise in nutritional biochemistry, and membership in notable committees such as the National Institutes of Health (NIH).

In 2008, Tsien received the Nobel Prize in Chemistry for his discovery of the green fluorescent protein (GFP) with his colleagues Osamu Shimomura and Martin Chalfie. He is a Howard Hughes Medical Institute Investigator and professor at the University of California-San Diego.

He focused on proteins called miniSOGs, which are single oxygen-generating miniproteins and genetic tags used in electron microscopy (EM). He said electrons are beamed at an object to produce a highly magnified image. These miniSOGs are sequences of amino acids that can be attached to proteins, Tsien noted. When miniSOGs are exposed to blue light, they produce a type of molecular oxygen that is visible in EM. The use of EM creates an amplified image under the microscope which is of a greater resolution than the image produced by light microscopy.

It is really amazing how many different applications there are for the tag, James Roed, post doctorate fellow at the School of Medicine noted. The design is simple yet so complex and is really going to revolutionize cancer treatment but has potential in being used to tether probes to drugs as well.

Tsien explained the clinical applications of fluorescent dyes in cancer research and treatment. This is a very nonselective process. Tsien explained. When you try to do this with a fluorescent tag IV injection into a mouse, you get a fluorescent tail, because it sticks to the epithelia, which is the skin of the animal, at the site of the injection.

It then travels to different regions of the body but practically never reaches the tumor that you care about, Tsien said.

We decided in our lab that what was necessary was a way of making this process selective, not just indiscriminate, he said.

He then showed images of tumors in mice and explained the difficulty the human eye experiences in differentiating a tumor from the surrounding flesh. When the tissue was exposed via fluorescent illumination, the boundaries of the tumor became easily distinguishable as the fluorescent light blue mass stood out.

See original here:
Nobel Laureate Explores Proteins, Surgery

Nick Denis trades in laboratory for the octagon

darren yourk From Friday's Globe and Mail Published Thursday, Mar. 01, 2012 8:23PM EST Last updated Friday, Mar. 02, 2012 8:42AM EST

Nick Denis can tell you what it feels like to knock a man out cold while thousands of fans roar their approval. He can also talk at length about proteomics the study of proteins and what it takes to finish a master degree in biochemistry.

Not a lot attention is paid to what goes on between the cauliflower ears of mixed martial arts fighters, but Denis, who walked away from the research lab one year short of getting his PhD from the University of Ottawa to focus on the octagon, is proof theres a lot more to the sport than power and toughness.

To be able to out-think an opponent is a huge advantage in a fight, Denis said. You have to understand how to react to situations and be analytical. It looks like just brute force in there, but theres actually technique and skill.

The Ottawa native roared into the bantamweight division of the Ultimate Fighting Championship in January, knocking out Joseph Sandoval with a series of elbow strikes just 22 seconds into the first round of his debut bout in Nashville an effort that earned him a $45,000 bonus cheque for knockout of the night. Hes now aiming to cement his status as an emerging talent when he returns to the octagon to face Johnny Bedford May 5 in East Rutherford, N.J.

After studying karate and tae kwon do in his youth, it was boredom with weightlifting workouts that got Denis started down the path to the UFC. He enrolled in a jiu-jitsu class with a friend as a new way to stay in shape and was hooked immediately. It wasnt long before he decided to train toward competing as an MMA fighter.

At the same time, Denis enrolled at the University of Ottawa, balancing a busy academic schedule in the world of analytical biochemistry with morning and evening training sessions.

Jeffrey Smith, a professor in the chemistry department at Carleton University who shared an office with Denis for almost three years at the University of Ottawa, calls him a gifted scientist.

He is really good with his hands, which is a big skill in the lab, Smith said. A lot of people have book smarts, but at the end of the day you have to have the manual dexterity to use the equipment and do things accurately. He was good at it, but Im not sure he enjoyed it all that much. MMA is really what hes passionate about.

While Denis showed up to the lab some days with a lumpy face and black eyes from training, Smith said it was his big personality that really made him stand out.

Read the original here:
Nick Denis trades in laboratory for the octagon

Cannabis Science Issues Potential Revenues And Market Data for the New Cannabis Science Brand OTC Products

DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis and hemp products, issues market data for the four Cannabis Science brand products for the newest over-the-counter line to be released.

The Global Anti-Aging Products Market to reach $291.9 Billion by 2015, and the U. S. Market for Anti-Aging Products for Appearance Enhancement is expected to be more than US$5.0 billion by 2015. The global cosmeceuticals market is US$ 27.2 Billionin 2010 according to a new report by Global Industry Analysts. The US market for skin irritation creams and sunscreen is $6.5 billion. US demand for cosmeceutical products is expected to increase 5.8 percent annually through 2015. The Global Lip Care Products Market is expected to reach $1.7 Billion by 2015. (reportlinker.com NEW YORK,Jan. 11, 2012/PRNewswire)

Cannabis Science is among the leading experts specializing in developing all natural organic bio healing hemp health, beauty and cosmetics products. Our philosophy is to bring the best products possible to the entire world, to help improve and promote a healthier natural way of life. Superior products are born from scientific data and research and we have come to a new understanding in the keys to our product development.

Dr. Moe Afaneh, Cannabis Science COO, explained, We believe our sunscreen and protectant is far superior to others, because we have invested time into understanding what occurs in the body and on the skin, and targeting the cascade of events that occurs when people get sunburned. We have meticulously targeted key components that lead to the sunburn and have created our elite formulation so that one instantly feels the skin begin to cool, the pain begins to dissipate and the healing process has begun. We have created our own cascade of healing properties using the finest natural ingredients to mimic our bodys natural pathway when responding to a skin burn.

Dr Afaneh added, Another of our topical skin care products helps provide relief to various skin conditions such as eczema and other recurring skin irritations. We have studied various populations and age groups that suffer from acute and chronic skin irritations. These symptoms varied from raised dry patches of skin, red blotches, hardened patches, mostly appearing in areas of the arms and legs, as well as areas of the body that tended to constantly rub against clothing or other surfaces. Our specialized formulation was designed based on understanding the patients expectations from over-the-counter skin care products. By understanding patients needs, we created our all natural unique formulation to help improve their quality of life on daily basis. It is designed to help stop the itching and pain, first and foremost, and then begins to lock moisture in and around the area, and then our natural blend of ingredients begins to help the body heal the skin and reduce the irritation.

Dr. Afaneh concludes with, Our anti-aging skin serum, specifically formulated for women, helps rejuvenate and soften the skin. The Cannabis Science serum uses only natural ingredients, including hemp oil extract and many other natural oils and ingredients. Our serum leaves the skin looking radiant, energized, softer, healthier, and full of life. Our all-natural lip balm that contains hemp oil extract and our unique blend of ingredients and is unique in that it has natural ingredients that help protect against bacteria and fungus. It also has SPF to protect against the harmful effects of the sun, and is infused with antioxidants and many other natural extracts to soften the lips and lock the moisture in.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

Read the rest here:
Cannabis Science Issues Potential Revenues And Market Data for the New Cannabis Science Brand OTC Products

Anatomy of a Winnipeg Jets Blowout: Fan's Take

A close game was expected between the Winnipeg Jets and the Southeast division-leading Florida Panthers on Thursday, March 1 at the MTS Centre. Let's just say the game didn't go according to plan, as the Jets routed the Panthers, 7-0. Here's a timeline of the evening's stunning events.

Fans cheer the Jets at the MTS Centre. Wikimedia Commons

7:32 p.m. Winnipeg comes into the game four points behind the Panthers in the Southeast and one point out of eighth place in the Eastern Conference. The home crowd senses the importance of the game, as the Jets take the ice to a vociferous, standing ovation. It'll get louder before the game is over.

7:43 p.m. Evander Kane steals the puck in Florida's zone, skates in alone and beats Panthers goaltender Jose Theodore at 4:01 of the first period for the first goal of the game. In the process, Kane extends his career-high point streak to eight games.

7:46 p.m. Jim Slater buries a rebound at 6:03 of the first to make it 2-0. Mark Stuart and Chris Thorburn draw assists on Slater's ninth goal of the season and first in 19 games. So much for the Panthers taking the crowd out of the game. Only a few minutes into the action, the MTS Centre is rocking.

8:13 p.m. End of the first period. Winnipeg leads the Panthers in both shots and hits at 13-7 and 15-7, respectively. The Jets are showing no ill effects from Monday's 5-3 loss to the Edmonton Oilers in which they allowed four unanswered goals in the third period.

9:01 p.m. End of the second period. The Jets still lead 2-0, but Florida controlled play for much of the middle frame, outshooting Winnipeg, 17-8. The Jets record this season when leading after three periods is 23-3-1. Conversely, Florida is 3-17-2 when trailing after three.

9:21 p.m. Kyle Wellwood tips home Stuart's blast from the top of the circle at 1:49 of the third period to make it 3-0. Kane draws the secondary assist for his second point of the game.

9:25 p.m. The Panthers turn over the puck in Winnipeg's zone, sparking an unheard of 5-on-1 rush the other way. Blake Wheeler ultimately feeds Bryan Little, who fires into an empty net for his 19th goal of the season to make it 4-0. Scott Clemmensen replaces Theodore to the delight of the MTSC crowd.

9:33 p.m. Nik Antropov bangs home a loose puck in front of the cage on the power play for his 10th goal of the seasonthe Jets lead, 5-0. Winnipeg entered the game with the top-ranked home power play in the National Hockey League. The Jets went 1-for-3 on the man advantage.

Read more from the original source:
Anatomy of a Winnipeg Jets Blowout: Fan's Take

How anesthetic isoflurane induces Alzheimer's-like changes in mammalian brains

ScienceDaily (Mar. 1, 2012) The association of the inhaled anesthetic isoflurane with Alzheimer's-disease-like changes in mammalian brains may by caused by the drug's effects on mitochondria, the structures in which most cellular energy is produced. In a study that will appear in Annals of Neurology and has received early online release, Massachusetts General Hospital (MGH) researchers report that administration of isoflurane impaired the performance of mice on a standard test of learning and memory -- a result not seen when another anesthetic, desflurane, was administered. They also found evidence that the two drugs have significantly different effects on mitochondrial function.

"These are the first results indicating that isoflurane, but not desflurane, may induce neuronal cell death and impair learning and memory by damaging mitochondria," says Yiying (Laura) Zhang, MD, a research fellow in the MGH Department of Anesthesia, Critical Care and Pain Medicine and the study's lead author. "This work needs to be confirmed in human studies, but it's looking like desflurane may be a better anesthetic to use for patients susceptible to cognitive dysfunction, such as Alzheimer's patients."

Previous studies have suggested that undergoing surgery and general anesthesia may increase the risk of Alzheimer's, and it is well known that a small but significant number of surgical patients experience a transient form of cognitive dysfunction in the postoperative period. In 2008, members of the same MGH research team showed that isoflurane induced Alzheimer's-like changes -- increasing activation of enzymes involved with cell death and generation of the A-beta plaques characteristic of the disease -- in the brains of mice. The current study was designed to explore the underlying mechanism and behavioral consequences of isoflurane-induced brain cell death and to compare isoflurane's effects with those of desflurane, another common anesthetic that has not been associated with neuronal damage.

In a series of experiments, the investigators found that the application of isoflurane to cultured cells and mouse neurons increased the permeability of mitochondrial membranes; interfered with the balance of ions on either side of the mitochondrial membrane; reduced levels of ATP, the enzyme produced by mitochondria that powers most cellular processes; and increased levels of the cell-death enzyme caspase. The results also suggested that the first step toward isoflurane-induced cell death was increased generation of reactive oxygen species -- unstable oxygen-containing molecules that can damage cellular components. The performance of mice on a standard behavioral test of learning and memory declined significantly two to seven days after administration of isoflurane, compared with the results of a control group. None of the cellular or behavioral effects of isoflurane were seen when the administered agent was desflurane.

In another study by members of the same research team -- appearing in the February issue of Anesthesia and Analgesia and published online in November -- about a quarter of surgical patients receiving isoflurane showed some level of cognitive dysfunction a week after surgery, while patients receiving desflurane or spinal anesthesia had no decline in cognitive performance. That study, conducted in collaboration with investigators from Beijing Friendship Hospital in China, enrolled only 45 patients -- 15 in each treatment group -- so its results need to be confirmed in significantly larger groups.

"Approximately 8.5 million Alzheimer's disease patients worldwide will need anesthesia and surgical care every year," notes Zhongcong Xie, MD, PhD, corresponding author of both studies and director of the Geriatric Anesthesia Research Unit in the MGH Department of Anesthesia, Critical Care and Pain Medicine. "Developing guidelines for safer anesthesia care for these patients will require collaboration between specialists in anesthesia, neurology, geriatric medicine and other specialties. As the first step, we need to identify anesthetics that are less likely to contribute to Alzheimer's disease neuropathogenesis and cognitive dysfunction." Xie is an associate professor of Anesthesia at Harvard Medical School (HMS)

Additional co-authors of the Annals of Neurology study are Zhipeng Xu, MD, PhD, Hui Wang, MD, and Yuanlin Dong, MD, MGH Anesthesia; Rudolph Tanzi, PhD, MGH Neurology; Hai Ning Shi, DVM, PhD, MGH Pediatrics; Deborah Culley, MD, and Greg Crosby, MD, Brigham and Women's Hospital; and Edward Marcantonia, MD, MS, Beth Israel Deaconess Medical Center. The study was supported by grants from the National Institutes of Health, the American Geriatrics Society, the Alzheimer's Association and the Cure Alzheimer's Fund.

Recommend this story on Facebook, Twitter, and Google +1:

Other bookmarking and sharing tools:

Story Source:

The rest is here:
How anesthetic isoflurane induces Alzheimer's-like changes in mammalian brains

Chemistry teacher, students examine causes, effects of global warming

Editor's Note: This article was completed as an assignment for a class in the A.Q. Miller School of Journalism and Mass Communications.

The noise of talking in the crowded classroom gradually subsided as Lou Wojcinski, K-State assistant teaching scholar of chemistry, displayed the following question through the class projection system:

"Do you think most scientists agree with one another about whether or not global warming is happening, or do you think there is a lot of disagreement among scientists on the issue?"

Wojcinski then instructed the students to answer the question with their I-clickers; 70 percent of the class responded that there is significant disagreement among scientists, whereas only 30 percent said that the issue is settled.

As the political global warming debate surges, this poll raises the question of whether or not scientists agree on the issue.

Wojcinski said roughly 90 percent of scientists agree that global warming is occurring.

"Projections about the future are much harder to do; I would say there is less agreement there," Wojcinski said.

Wojcinski said there are a variety of factors that contribute to global warming.

"There is a human contribution to increased temperatures," he said. "I think it is important to say that it is not just a human contribution. There are natural contributions to the temperatures that we have, and I think that what some people think when they hear that it's a human-caused problem they think it's just a human-caused problem, which sounds a little silly. I think part of the hesitancy in accepting the science comes from people interpreting it as solely a human problem."

Besides disagreeing about what scientists think, students at K-State also have differing views about what global warming is and its implications for the future.

Read more:
Chemistry teacher, students examine causes, effects of global warming

Nepal plans biotechnology centre

Nepal plans to set up a national biotech centre.

Ashden Awards

[KATHMANDU] Nepals ministry of science and technology plans to establish by 2013 a national biotechnology centre (NBC) to promote research and development in agriculture, health, environment and industry.

By setting up the new centre estimated to cost US$ 13 million over five years Nepal hopes to follow the success of its neighbours China and India in biotechnology.

"But without a proper government entity in place you cannot do that," Sameer Dixit, country director of the non-profit Centre for Molecular Dynamics, Nepal, and team leader for the NBC project planning, told SciDev.Net.

Nepal has no government agency to oversee biotechnology development and there has been no significant advance since 1982 when the Nepal Academy of Science and Technology, started a biotechnology unit.

It took until 1997 before a second biotechnology unit could be set up at the Nepal Agriculture Research Council (NARC).

In 2003 Kathmandu University launched the first undergraduate degree in biotechnology and by 2009 Tribhuvan University, Nepals oldest and largest public university, had established a masters programme.

The university programmes produced 50 degree holders per year, but with no industry or job market to assimilate them many had to seek opportunities abroad.

"It seemed like we were teaching biotechnology just to export people to foreign countries en masse," observed Mukunda Ranjit, president of the Nepal Biotechnology Association, who is also involved in planning for the NBC.

See the rest here:
Nepal plans biotechnology centre

Black Americans die up to 8 years sooner in some states

In every state across the country, white men and women are outliving blacks, in some cases by a margin as wide as eight years, says a new life-expectancy study from theUniversity of California, Los Angeles.

In America, a white male born today has a life expectancy of 74.8 years, while black males are expected to live to 67.7, creating a seven-year disparity. Meanwhile, white women can expect to live to 79.8, while their black counterparts have a life expectancy five years shorter, at 74.6 years, said the UCLA report.

Overall, the life-expectancy gap nationwide seems to be narrowing slightly, according to researchers, but it continues to vary widely by state.

In Florida, the longevity gap for women is among the widest of any state, at seven years. The life expectancy here for black women is 74, while it's 80.9 for white women, said the study, which appeared in this month's issue of Health Services Research. Life expectancy is defined as how long a person born today is expected to live.

That gap is mostly because white women live longer than average in the Sunshine State, said Dr. Nazleen Bharmal, the study's lead researcher and a clinical instructor of medicine at the David Geffen School of Medicine at UCLA.

The gap for Florida men is in line with the national average: 75.2 years for white males and 67.8 for black males.

Washington, D.C., had the largest disparity between blacks and whites. at 13.8 years for men and 8.6 for women, said the researchers, who studied national death-certificate data from nearly 18 million non-Hispanic blacks and non-Hispanic whites who died from 1997 to 2004.

New Mexico had the smallest disparity between blacks and whites, at 3.8 years for men and 2.5 for women.

Bharmal warns, however, that although closing the gap is a worthy public-health goal, that shouldn't be the focus.

Where small disparities in life expectancy exist, that happens because the white populations are doing as poorly as black populations, she said.

More here:
Black Americans die up to 8 years sooner in some states

Premature Ovarian Aging Expert Issues Fertility Tip Sheet for Women Interested in Pregnancy Over 40

New Yorks Center for Human Reproduction releases special advice for women over 40 interested in becoming pregnant.

New York, NY (PRWEB) March 01, 2012

Its important to recognize the urgency of aggressive fertility treatment when you are above age 40, says Dr. Gleicher, Medical Director of CHR, which released the tip sheet. As women get older, their ovarian reserve (a measure of ovaries ability to produce good-quality eggs) declines. Because this process of ovarian aging speeds up significantly after age 40, timely diagnosis of infertility becomes crucial especially after age 40. Every fertility treatment loses efficacy rapidly with declining ovarian reserve.

As a fertility center of last resort for patients with diminished ovarian reserve, CHR sees a large number of women over 40 with premature ovarian aging. Dr. Gleicher continues: There isnt a day when we dont hear our patients say doctor, I wish Id known about your center years ago, when I was doing such and such... The earlier we can start treatment, the better, of course, our chances of helping our patients! This is why we are issuing this fertility tip sheet.

CHRs fertility tips for women trying to get pregnant after 40 include:

About Center for Human Reproduction

Center for Human Reproduction, or CHR (http://www.centerforhumanreprod.com), is a leading fertility center in the United States with a worldwide reputation as a "fertility center of last resort," specializing in treatment of infertility in women with diminished ovarian reserve, including younger women with premature ovarian aging (POA) and older women with physiological ovarian aging. Dr. Gleicher is available for additional comments.

###

Communications Manager Center for Human Reproduction (212) 994-4400 4491 Email Information

See more here:
Premature Ovarian Aging Expert Issues Fertility Tip Sheet for Women Interested in Pregnancy Over 40

Researchers Find Five Novel Gene Mutations Linked to Platelet Counts in African Americans

--Findings could be a step toward developing better drugs for coronary artery disease and preventing heart attacks

Newswise Researchers, led by scientists from Johns Hopkins, have found five previously unknown gene mutations believed to be associated with elevated blood platelet counts in African-Americans, findings they say could someday lead to the development of new drugs to help prevent coronary artery disease.

The study is believed to be the first of its size to focus on platelet genetics in African Americans, who have a higher risk of stroke than other racial groups. They also have relatively higher platelet counts and average platelet volume, and worse outcomes than whites after a heart attack.

Improving our understanding of the biology and genetics of platelets and how they function will aid us in developing better treatments and more individualized treatments to reduce risk of heart disease associated with platelets, says study leader Rehan Qayyum, M.D., an assistant professor in the division of general internal medicine at the Johns Hopkins University School of Medicine.

Qayyum cautions that there are believed to be many more genes involved in platelet function that remain unknown.

Platelets are cells produced in bone marrow, smaller than red or white blood cells, which foster blood clotting. While clotting is critical to stop bleeding after injuries, it can also cause harm by allowing clumps of blood cells to clog blood vessels leading to the heart, brain and other organs, cutting off blood flow.

Studies have shown that the greater the platelet volume or count in the blood, and the larger platelets are, the greater the risk of dangerous clot formation. Qayyum notes that the number of platelets in a given amount of blood (platelet count) and the size of these platelets (measured as average platelet count) vary from person to person in much the way that height, weight and eye color traits differ. Thus, he said, the search for genes that control this variation is a potentially fruitful line of scientific inquiry.

Qayyum and his colleagues, publishing in the online journal PLoS Genetics, report that they conducted a meta-analysis and genomewide association study, looking at genetic data from 16,000 African-American participants from seven separate studies. They compared information from each study, tracking 2.5 million single possible changes in the human genetic code to see which genes stood out across the entire group as significantly associated with increased or decreased platelet counts.

The researchers found five such alterations, involving the addition or deletion of a single piece of genetic code, across the studied genomes that had not been identified in other populations. When they checked their findings against data from Caucasian and Hispanic groups, they found three of the novel gene mutations in those populations, too. Four of the previously unknown gene mutations were later found in the genetic code of platelet cells, but one was not. That one, however, was found close to a gene that is known to be essential in the formation of normal platelets. The exact role played by each of these mutations still needs to be determined, Qayyum says.

Qayyum says one goal of their research is to identify new targets for drugs that decrease platelet aggregation in the arteries and prevent clot formation. Blood thinners, including aspirin, clopidogrel and warfarin, are widely used antiplatelet medications. But some people cant tolerate the side effects, which include bleeding, bruising and gastrointestinal upset.

More:
Researchers Find Five Novel Gene Mutations Linked to Platelet Counts in African Americans

Researchers find 5 novel gene mutations linked to platelet counts in African Americans

Public release date: 1-Mar-2012 [ | E-mail | Share ]

Contact: Stephanie Desmon sdesmon1@jhmi.edu 410-955-8665 Johns Hopkins Medical Institutions

Researchers, led by scientists from Johns Hopkins, have found five previously unknown gene mutations believed to be associated with elevated blood platelet counts in African-Americans, findings they say could someday lead to the development of new drugs to help prevent coronary artery disease.

The study is believed to be the first of its size to focus on platelet genetics in African Americans, who have a higher risk of stroke than other racial groups. They also have relatively higher platelet counts and average platelet volume, and worse outcomes than whites after a heart attack.

"Improving our understanding of the biology and genetics of platelets and how they function will aid us in developing better treatments and more individualized treatments to reduce risk of heart disease associated with platelets," says study leader Rehan Qayyum, M.D., an assistant professor in the division of general internal medicine at the Johns Hopkins University School of Medicine.

Qayyum cautions that there are believed to be many more genes involved in platelet function that remain unknown.

Platelets are cells produced in bone marrow, smaller than red or white blood cells, which foster blood clotting. While clotting is critical to stop bleeding after injuries, it can also cause harm by allowing clumps of blood cells to clog blood vessels leading to the heart, brain and other organs, cutting off blood flow.

Studies have shown that the greater the platelet volume or count in the blood, and the larger platelets are, the greater the risk of dangerous clot formation. Qayyum notes that the number of platelets in a given amount of blood (platelet count) and the size of these platelets (measured as average platelet count) vary from person to person in much the way that height, weight and eye color traits differ. Thus, he said, the search for genes that control this variation is a potentially fruitful line of scientific inquiry.

Qayyum and his colleagues, publishing in the online journal PLoS Genetics, report that they conducted a meta-analysis and genomewide association study, looking at genetic data from 16,000 African-American participants from seven separate studies. They compared information from each study, tracking 2.5 million single possible changes in the human genetic code to see which genes stood out across the entire group as significantly associated with increased or decreased platelet counts.

The researchers found five such alterations, involving the addition or deletion of a single piece of genetic code, across the studied genomes that had not been identified in other populations. When they checked their findings against data from Caucasian and Hispanic groups, they found three of the novel gene mutations in those populations, too. Four of the previously unknown gene mutations were later found in the genetic code of platelet cells, but one was not. That one, however, was found close to a gene that is known to be essential in the formation of normal platelets. The exact role played by each of these mutations still needs to be determined, Qayyum says.

Visit link:
Researchers find 5 novel gene mutations linked to platelet counts in African Americans

Nuvilex’s Diabetes Treatment Utilizing Implanted Encapsulated, Insulin-Producing Cells Potentially Eliminates Need for …

SILVER SPRING, Md.--(BUSINESS WIRE)--

Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today provided additional details based on the Goldman Small Cap Research report issued February 29, 2012, that highlighted the companys cell encapsulation technology and its benefits for treating chronic diseases such as diabetes. The Companys technology involves encapsulating insulin-producing cells that respond to changes in glucose levels into the Cell-in-a-Box platform. As a result, the treatment would potentially eliminate the need for diabetes patients to continually test their glucose levels and inject insulin.

The Goldman report cited the completed animal study wherein SG Austria successfully treateddiabetesin an established, recognized animal model utilizing liveencapsulatedcells. In the study, the introduced cells responded to elevated blood sugar levels by producing insulin, thereby alleviating thesymptoms of diabetes. Moreover, encapsulated cells remained viable and responsive for many months.

The report stated, This data, as well as previously published results, demonstrate it is feasible to overcome the basis for diabetes by implanting encapsulated, insulin-producing cells. This should pave the way for future clinical trials of encapsulated cells as a means to continuously regulate blood glucose for months, eliminating the need for daily glucose assessment and insulin injections. Such treatment would present a more natural means of providing insulin to patients, mimicking the body's own insulin production and thereby maintaining healthy blood glucose levels.

The long term effects of diabetes include kidney failure, blindness, heart disease, amputations, and stroke. The World Health Organization (WHO) reports346 million people in the world have diabetes and 4 million deaths occur globally each year. In fact, more than $378 billion is spent annually on diabetes treatment with the number expected to rise to $490 billion by 2030.

The report concluded that, Although it is early in the development process, the prospects on the diabetes front could be huge for the Company. Goldman set a current value of Nuvilex at $0.30 per share with a six month price target of $0.50 per share based on the cell encapsulation technology and the favorable clinical and pre-clinical trial results across multiple biotechnology fields.

Dr. Robert Ryan, Chief Executive Officer of Nuvilex, added, We are hopeful that through use of our cell encapsulation platform patients will no longer have to rely on daily insulin injections. The ultimate objective, if future trials prove effective, will be for patients to receive encapsulated live cell treatments intermittently, possibly as infrequently as every 3 to 6 months or longer, dramatically changing their lives.

Investors are recommended to study the Goldman Research Report for a detailed review and valuation methodology regarding Nuvilex.

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of biotechnology and clinically useful, therapeutic live-cell encapsulation products and services for the research and medical communities. Through substantial effort, Nuvilex and SG Austria are rapidly moving toward our initial phase of funding acquisition and initial agreement completion. One of our first planned offerings is to include cancer treatments using the companys industry-leading live-cell encapsulation technology.

Original post:
Nuvilex’s Diabetes Treatment Utilizing Implanted Encapsulated, Insulin-Producing Cells Potentially Eliminates Need for ...

UQ Summer Research Program provides wealth of new experiences

Adam Hand at UQ's AIBN

Mr Hand crossed the country and spent Christmas away from his family to learn about bioengineering at the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland.

During his break from undergraduate engineering studies at Edith Cowan University, the 23-year-old from Tuart Hill spent 12 weeks at the AIBN as part of a Summer Research Scholarship Program.

Mr Hand spent the time in the lab of AIBN Professor Mark Kendall to learn about the Nanopatch, a needle-free vaccination device with thousands of small projections designed to deliver vaccine to immune cells in the skin.

In only 12 weeks I believe I have experienced more and learnt more than I could have ever hoped to learn in a classroom, he said.

The program has opened my eyes to a completely different and fascinating field that I would have never imagined entering when originally enrolling in engineering.

Mr Hand spent his time in the lab improving and automating the dry coating procedure of vaccines for use on the Nanopatch.

He admitted to being completely overwhelmed when he arrived in Brisbane, moved into a share-house and started his research project at AIBN.

When I first arrived in Brisbane I was thrust into a new city, a new house and more dauntingly this new experience of bioengineering.

You may ask: why did you throw away a summer holiday to work at AIBN?'. However, that wasn't the case. Travelling from Perth and experiencing a new life was an adventure in itself and working at the AIBN was an opportunity that I would not have missed.

Read more from the original source:
UQ Summer Research Program provides wealth of new experiences

Nobel Laureate Explores Proteins, Surgery

Nobel Laureate in Chemistry Roger Tsien discussed current research on fluorescent proteins, or proteins that emit bright colors when exposed to ultraviolet blue light, and their uses in surgery at Emory on Thursday.

The Department of Biochemistry held the lecture, titled Breeding and Building molecules to Spy on Cells and Disease Processes, at the Woodruff Health Sciences building as part of the Department of Biochemistrys annual Donald B. McCormick Lecture. The annual lecture honors McCormick, who served as the chair of the department from 1979 to 1994 and is currently professor emeritus at Emorys School of Medicine.

McCormick is recognized for his many achievements including the publication of more than 500 papers, leading expertise in nutritional biochemistry, and membership in notable committees such as the National Institutes of Health (NIH).

In 2008, Tsien received the Nobel Prize in Chemistry for his discovery of the green fluorescent protein (GFP) with his colleagues Osamu Shimomura and Martin Chalfie. He is a Howard Hughes Medical Institute Investigator and professor at the University of California-San Diego.

He focused on proteins called miniSOGs, which are single oxygen-generating miniproteins and genetic tags used in electron microscopy (EM). He said electrons are beamed at an object to produce a highly magnified image. These miniSOGs are sequences of amino acids that can be attached to proteins, Tsien noted. When miniSOGs are exposed to blue light, they produce a type of molecular oxygen that is visible in EM. The use of EM creates an amplified image under the microscope which is of a greater resolution than the image produced by light microscopy.

It is really amazing how many different applications there are for the tag, James Roed, post doctorate fellow at the School of Medicine noted. The design is simple yet so complex and is really going to revolutionize cancer treatment but has potential in being used to tether probes to drugs as well.

Tsien explained the clinical applications of fluorescent dyes in cancer research and treatment. This is a very nonselective process. Tsien explained. When you try to do this with a fluorescent tag IV injection into a mouse, you get a fluorescent tail, because it sticks to the epithelia, which is the skin of the animal, at the site of the injection.

It then travels to different regions of the body but practically never reaches the tumor that you care about, Tsien said.

We decided in our lab that what was necessary was a way of making this process selective, not just indiscriminate, he said.

He then showed images of tumors in mice and explained the difficulty the human eye experiences in differentiating a tumor from the surrounding flesh. When the tissue was exposed via fluorescent illumination, the boundaries of the tumor became easily distinguishable as the fluorescent light blue mass stood out.

Continue reading here:
Nobel Laureate Explores Proteins, Surgery

Nationwide Children's Hospital neuromuscular disorder podcasts now available on iTunes

Public release date: 1-Mar-2012 [ | E-mail | Share ]

Contact: Erin Pope Erin.Pope@NationwideChildrens.org 614-355-0495 Nationwide Children's Hospital

In 2010, the Center for Gene Therapy at Nationwide Children's Hospital launched a monthly podcast entitled, "This Month in Muscular Dystrophy," featuring internationally known scientists discussing the latest research in muscular dystrophy and other neuromuscular disorders. Now, these podcasts will be available for users on iTunes and at http://www.NationwideChildrens.org/muscular-dystrophy-podcast.

The podcasts are geared toward patients, their families and primary care physicians who take care of patients with neuromuscular diseases. Hosted by Kevin Flanigan, MD, an attending physician in Neurology at Nationwide Children's Hospital, and a principal investigator in the Center for Gene Therapy in The Research Institute at Nationwide Children's, the programs include interviews with authors of recent scientific publications discussing how their work improves understanding of inherited neuromuscular diseases and what their findings might mean for treatment.

New programs available for download on iTunes include:

Podcasts from previous months have also been uploaded to iTunes and are available for download.

"There is a lot of exciting work going on in the field of neuromuscular disease, and for patients and their families, it may be hard to get access to information about new results," said Dr. Flanigan, also a professor of Pediatrics and Neurology at The Ohio State University College of Medicine. "Our goal in offering this monthly podcast is to provide a way for people affected by the muscular dystrophies and related disorders to hear directly from top researchers about their latest results. It's my job to converse in understandable terms with these researchers about what is useful or exciting in their work."

Patients and their families are eager to find reliable information, especially about what new therapies are entering trials. With these podcasts available on iTunes, patients and their families have access to this information at their fingertips. These monthly podcasts provide reliable information directly from leading scientists and physicians in the field to empower patients to take the information they learn into their own clinics to discuss with their doctors. The podcasts also serve to provide reliable information to primary care physicians who often have the most contact with patients who have neuromuscular disorders.

"Through these podcasts, I think we can reinforce the hope shared by all families, and let them know that many pathways that may lead to meaningful treatments are being explored," Dr. Flanigan added.

Dr. Flanigan's primary research interest is in the genetic and molecular characterization of inherited neuromuscular diseases particularly muscular dystrophies and in the development of therapies directed toward these diseases.

Continue reading here:
Nationwide Children's Hospital neuromuscular disorder podcasts now available on iTunes

Nick Denis trades in laboratory for the octagon

darren yourk From Friday's Globe and Mail Published Thursday, Mar. 01, 2012 8:23PM EST Last updated Thursday, Mar. 01, 2012 8:25PM EST

Nick Denis can tell you what it feels like to knock a man out cold while thousands of fans roar their approval. He can also talk at length about proteomics the study of proteins and what it takes to finish a master degree in biochemistry.

Not a lot attention is paid to what goes on between the cauliflower ears of mixed martial arts fighters, but Denis, who walked away from the research lab one year short of getting his PhD from the University of Ottawa to focus on the octagon, is proof theres a lot more to the sport than power and toughness.

To be able to out-think an opponent is a huge advantage in a fight, Denis said. You have to understand how to react to situations and be analytical. It looks like just brute force in there, but theres actually technique and skill.

The Ottawa native roared into the bantamweight division of the Ultimate Fighting Championship in January, knocking out Joseph Sandoval with a series of elbow strikes just 22 seconds into the first round of his debut bout in Nashville an effort that earned him a $45,000 bonus cheque for knockout of the night. Hes now aiming to cement his status as an emerging talent when he returns to the octagon to face Johnny Bedford May 5 in East Rutherford, N.J.

After studying karate and tae kwon do in his youth, it was boredom with weightlifting workouts that got Denis started down the path to the UFC. He enrolled in a jiu-jitsu class with a friend as a new way to stay in shape and was hooked immediately. It wasnt long before he decided to train toward competing as an MMA fighter.

At the same time, Denis enrolled at the University of Ottawa, balancing a busy academic schedule in the world of analytical biochemistry with morning and evening training sessions.

Jeffrey Smith, a professor in the chemistry department at Carleton University who shared an office with Denis for almost three years at the University of Ottawa, calls him a gifted scientist.

He is really good with his hands, which is a big skill in the lab, Smith said. A lot of people have book smarts, but at the end of the day you have to have the manual dexterity to use the equipment and do things accurately. He was good at it, but Im not sure he enjoyed it all that much. MMA is really what hes passionate about.

While Denis showed up to the lab some days with a lumpy face and black eyes from training, Smith said it was his big personality that really made him stand out.

Here is the original post:
Nick Denis trades in laboratory for the octagon

Ellen Pompeo: Katherine Heigl's Return To 'Grey's Anatomy' Is Unlikely (VIDEO)

Ellen Pompeo is downplaying the rumors about Katherine Heigl returning to "Grey's Anatomy."

The actress stopped by "Chelsea Lately" (weekdays, 11 p.m. EST on E!) to promote the ABC medical drama. When she wasn't talking tequila and making out on camera, Pompeo was shooting down the rumors that her former co-star Heigl seemingly started while promoting her film "One For the Money."

"So wait, what's going on? Is Katherine Heigl coming back to the show?" Handler asked Pompeo.

"I don't think so," Pompeo said, shaking her head.

Handler pressed further and Pompeo said, "No, I don't think that's happening."

During her January press tour, Heigl said she was ready to return to "Grey's Anatomy," and told the powers that be at the series that she wants to come back.

"I really, really, really want to see where [Izzie] is," Heigl told E! "I just want to know what happened to her and where she went and what she's doing now."

Pompeo's comments come as Season 8 of "Grey's Anatomy" -- and her contract with the show -- come to a close. Both Pompeo and co-star Patrick Dempsey have been vocal about their desire to remain with the series, while remaining vague.

"I would never turn up my nose at 'Grey's' ... If I hear from the fans that they want us to keep going, then I would continue because we owe them everything," Pompeo told TV Guide in October.

TV Replay scours the vast television landscape to find the most interesting, amusing, and, on a good day, amazing moments, and delivers them right to your browser.

See more here:
Ellen Pompeo: Katherine Heigl's Return To 'Grey's Anatomy' Is Unlikely (VIDEO)

There’s no sense in revising the psychiatrist’s bible

Forget the Diagnostic and Statistical Manual of Mental Disorders we need a new system based on brain physiology, says psychiatrist Nick Craddock

You don't believe we should update the Diagnostic and Statistical Manual (DSM) used to classify mental illness. Why not? There are many reasons we should pause. The DSM checklist of symptoms is not fit for purpose: its categories don't map onto the emerging science of emotion and cognition, yet the DSM-5 rewriters plan to pull in more areas in the new categories and over-medicalise the situation further. Obviously the people rewriting DSM are not stupid, but the project is the wrong thing now. There are lots of great findings coming out of biology, neuroscience and psychology. We will need a new diagnostic system based on these.

How do you see a non-DSM system of classifying mental illness? It should be based on brain physiology, and make sense in biological and psychological terms. People think mental health is very different from physical health but I think our understanding of it is similar to where we were 100 years ago with illnesses such as diabetes. Take schizophrenia - people vary so much, but the DSM definition doesn't capture that. In 20 years' time the condition will have a biological and psychological typology. Right now our approach is like a blunderbuss.

What changes in DSM-5 worry you? Suppose you suffer from severe low mood, lack of energy and lack of self-esteem for two weeks continuously. As things stand, if this happens up to six months after a bereavement, it would be considered normal. For most of us that fits with common sense. DSM-5 drops that exclusion and classifies such an episode as depression. This seems unhelpful, to say the least.

What about the "temper tantrum" category? DSM-5 plans to bring in "Disruptive mood dysregulation disorder" which refers to an onset of temper outbursts before age 10. The thinking is this may be a prelude to later bipolar disorder. However, I believe we need much more firm evidence for the benefits of doing this before labelling children with such a diagnosis.

Do you have any other concerns? There's likely to be a move to include people with mild delusions, hallucinations or disorganised speech into the psychosis category as "an attenuated form with intact reality testing". This underlines the overwhelming criticism of DSM - we need more research to distinguish correctly between normal and abnormal states before it is clinically justified to add a new diagnosis like this.

DSM is American. Does it apply in Europe? In Europe we look more to the World Health Organization's International Classification of Disease in our clinical work, but DSM does guide research here.

How strong is the opposition to DSM-5? There is widespread scepticism globally because of the issues I have mentioned and the DSM's poor ability to translate outside the context of the US healthcare system. Over 11,000 people working in or concerned with mental health care have signed a petition calling for a rethink.

Nick Craddock is professor of psychiatry at the Institute of Psychological Medicine and Clinical Neurosciences at Cardiff University School of Medicine, and is the director of the Welsh National Centre for Mental Health

If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.

Original post:
There's no sense in revising the psychiatrist's bible

Nutrition Labels on Meat Now a Must

Following years of planning and several extensions, nutrition labels are now required on ground meat and poultry packages, and on or near major cuts sold in supermarkets, effective March 1.

This nutrition information will confirm for consumers what the latest U.S. Dietary Guidelines for Americans recently said, that lean meat and poultry products are an important part of a healthy balanced diet, declared J. Patrick Boyle, president of the American Meat Institute. This final rule has been in progress for more than a decade, and the meat and poultry industry is pleased to provide nutrient content information to consumers about our fresh products.

Nutrition labels have been required on processed meat and poultry products for many years, and many fresh single-ingredient meat and poultry products like steak, tenderloins and ground beef also have carried labels voluntarily. Now, this valuable information will be offered more widely and will provide a pleasant nutrition surprise to many meat and poultry consumers, Boyle said.

Meat and poultry products, Boyle noted, are nutrient dense and rich in protein, vitamins and minerals. Consumers should note that 29 cuts of beef, pork and lamb are considered lean. A 3-ounce serving of meat or poultry contains between 160 and 200 calories and contains all nine essential amino acids, he said. That is why meat is considered a complete protein.

Boyle said recent research has shown that lean meat and poultry provide a sense of satisfaction that help control hunger and aid in weight control. More than 40 cuts of meat and poultry qualify for the definition of lean.

AMI has produced a video to educate retailers and consumers about lean cuts of meat and poultry.

The Washington, D.C.-based American Meat Institute is a national trade association that represents companies that process 95 percent of red meat and 70 percent of turkey in the United States and their suppliers throughout the country.

Read more:
Nutrition Labels on Meat Now a Must